FDA Approves Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older

FDA News, New FDA Approvals
August 7, 2020
A+ A-
Email Print

Article Link: FDA Approves Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older

South San Francisco, CA — August 7, 2020 — Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post